 BUFFALO, N.Y., July 06, 2021 GLOBE NEWSWIRE -- Athenex, Inc., NASDAQ: ATNX, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration FDA during the second quarter of 2021 to discuss the deficiencies raised in the Complete Response Letter CRL received in February. 